MedTrace Logo

Developing Novel Circulating Epigenetic Biomarkers for Early Detection of Lung Cancer

NCT04814407 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2024-06-18

No results posted yet for this study

Summary

The investigators aim to identify novel circulating methylated biomarkers for early lung cancer detection as well as to develop new technologies that are clinically applicable with high sensitivity and specificity.

Conditions

Interventions

DIAGNOSTIC_TEST

Blood-derived DNA methylation detection

Up to 20 ml of blood will be collected from each subject, and the blood specimen will be processed to isolate plasma cell-free DNA and immune-derived cells (circulating T cells). Circulating methylated tumor/immune signature will then be identified.

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Hsing-Chen Tsai, M.D., Ph.D · Graduate institute of Toxicology, NTUCM; Department of Internal Medicine, NTUH

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2025-12-31
Completion
2027-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04814407 on ClinicalTrials.gov